Adult patients with idiopathic macular telangiectasia type 2 (MacTel) experience progressive retinal neurodegeneration that can significantly impact their functional vision and quality of life, despite having only minimal changes in their visual acuity. Revakinagene taroretcel (NT-501) is a new encapsulated cell therapy shown to slow disease progression. Join our faculty to hear the latest data around this new treatment and how their management practices are evolving to incorporate this new therapeutic option.
Rethinking MacTel: Cell-based Insights for Vision Preservation
10
episodes
1.00 program credits1h 03m
Details
Presenters
Target Audience
This certified continuing education (CME) activity is designed for ophthalmologists involved in the management of patients with retinal diseases.
Grantor Statement
This activity is supported by an independent educational grant from Neurotech Pharmaceuticals.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Appraise anatomic and functional measures of disease progression in macular telangiectasia (MacTel) type 2
- Evaluate the potential need for and the timing of treatment in patients with MacTel type 2
- Examine novel treatment approaches for MacTel type 2
- Analyze key efficacy and safety data from clinical trials evaluating novel therapies for MacTel type 2
Accreditation and Credit Designation Statements
Provided by Evolve Medical Education
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Faculty
Thomas Albini, MD
Bascom Palmer Eye Institute
University of Miami
Miami, FL
Dean Eliott, MD
Massachusetts Eye & Ear
Harvard Medical School
Boston, MA
Roger A. Goldberg, MD, MBA
Partner, Bay Area Retina Associates
Walnut Creek, CA
Faculty, CPMC Ophthalmology Residency
San Francisco, CA
Charles C. Wykoff, MD, PhD, FACS
Retina Consultants of Texas
Blanton Eye Institute
Houston Methodist Hospital
Houston, TXDisclosure of Relevant Financial Relationships
DISCLOSURE POLICY
In accordance with the ACCME Standards for Integrity and Independence, it is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that have identified and mitigated financial relationships and conflicts of interest to ensure independence, objectivity, balance, and scientific accuracy prior to this educational activity.
The following faculty/staff members have reported financial relationships with ineligible companies within the last 24 months.Thomas Albini, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Adverum Biotechnologies, Alcon, Apellis Pharmaceuticals, Applied Genetic Technologies Corp., Bausch + Lomb, Beaver-Visitec International, Clearside Biomedical, EyePoint Pharmaceuticals, Genentech, Mallinckrodt Pharmaceuticals, Neurotech Pharmaceuticals, Novartis, and Regenxbio.
Roger A. Goldberg, MD, MBA, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Adverum Biotechnologies, Alimera Sciences, Annexon, Apellis Pharmaceuticals, Boehringer Ingelheim, Carl Zeiss Meditec, Clearside, EyePoint Pharmeceuticals, Genentech, Janssen, Neurotech Pharmaceuticals, Ocular Therapeutix, Opthea, Orasis, StealthBio, and Regeneron. Advisory Board: Emmetrope Ophthalmics. Grant/Research Support: 4DMT, AbbVie, Affamed, Alexion, Annexon, Apellis Pharmaceuticals, Avirmax, Boehringer Ingelheim, Carl Zeiss Meditec, Clearside, Cognition, EyePoint Pharmaceuticals, Genentech, Janssen, Neurotech/LMRI, NovoNordisk, Ocular Therapeutix, StealthBio, Regeneron, and UnityBio. Speaker's Bureau: Apellis Pharmaceuticals.Dean Eliott, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Aldeyra Therapeutics, Alcon, Apellis Pharmaceuticals, AsclepiX Therapeutics, Aviceda Therapeutics, Clearside Biomedical, EyeBio, ExOcular DX, GelMEDIX, Genentech, Neurotech Pharmaceuticals, Ocular Therapeutix, and Pykus Therapeutics.
Charles C. Wykoff, MD, PhD, FACS,has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: 4DMT, AbbVie, ADARx, Adverum Biotechnologies, Alcon, Alimera Sciences, Alkeus, Allgenesis, AMC Sciences, Annexon, Apellis Pharmaceuticals, Ascidian, Astellas, Aviceda, Bausch + Lomb, Bayer, Biocryst, Bionic Vision, Boehringer Ingelheim, Carl Zeiss Meditec, Chengdu Kanghong Biotechnology, Curacle, Emmecell, Eyebiotech, EyePoint Pharmaceuticals, Frontera, Genentech, InGel, Janssen, Kiora, Kodiak Sciences, Kowa, Nanoscope, Neurotech Pharmaceuticals, NGM Biopharmaceuticals, Novartis, Oak Bay Bio, Ocular Therapeutix, OcuTerra, Ollin, ONL, Opthea, Opus, Osanni, Oxular, Palatin, Panther, PerceiveBio, Perfuse, PolyPhotonix, Ray, RecensMedical, Regeneron, Regenxbio, RetinAI, Roche, Samsung Bioepis, Sandoz, Sanofi, Santen, Skyline, Stealth, Suzhou Raymon, Sylentis, TCG Crossover, Théa Pharma, Therini, TissueGen, VH401, Vitranu, and Visgenx. Grant/Research Support: 4DMT, AbbVie, Adverum Biotechnologies, AffaMed, Alexion, Alimera Sciences, Allgenesis, Amgen, Annexin, Annexon, Apellis Pharmaceuticals, Ascidian, AsclepiX Therapeutics, Astellas, Aviceda, Avirmax, Bayer, Boehringer Ingelheim, Chengdu Kanghong Biotechnology, Clearside Biomedical, Curacle, Eluminex, EyeBiotech, EyePoint Pharmaceuticals, Genentech, IONIS, iRENIX, Janssen, Kalaris, Kodiak Sciences, Kyoto DDD, Kyowa Kirin, Nanoscope, Neurotech, NGM Biopharmaceuticals, Novartis, Ocugen, Ocular Therapeutix, Oculis, OcuTerra, OliX, Opthea, Outlook Therapeutics, Oxular, Oxurion, Oyster Point Pharma, PerceiveBio, Pykus, Regeneron, Regenxbio, Rezolute, Roche, Shanghai Henlius, Stealth, Skyline, and VH401.
The Evolve staff, planners and peer reviewer have no financial relationships with ineligible companies.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Neurotech Pharmaceuticals.This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
